Poziotinib phase 2 trial in lung cancer, NCT03066206, was updated. Now this study is recruiting not only patients with EGFR Exon 20 insertion mutations but also patients with HER2 exon 20 mutations. From the beginning of this trial I wondered why don't they study Poziotinib against HER2 mutations. Now they do. It is a very important update. It doubles patient population in lung cancer which can be treated with Poziotinib.
Investing, like life, is a journey. Both endeavors are easier to endure with company. I’ll let Dave Matthews explain the rest.
Let’s look at the numbers. SPPI has made it easy to follow the old portfolio of late, with 7 green weeks out of 8. This week was one of the more impressive of the bunch: a gain of 59 cents (7.83%), for a close at $8.12. The stock last closed above 8 in late 2014.
YTD, the comparison is among the leaders in the market. Recall that the closing price on 12/31/16 was $4.43. That makes the 2017 gain 83.3%.
The sector had a pretty good week. The NAS gained a respectable 1.2%; its yearly gain is a robust 18.6%. My bio indicators were better: the BTK gained an even 3%. The IBB had a nice gain of 2.67%, while the XBI progressed by 2.15%. The broader health care XLV was up 1.07%.
On 7/21/16, SPPI closed at $6.50. So YoY, there is a gain of 20.5%.
Here are the daily ranges for the week:
M 7.50-7.68 T 7.52-7.73 W 7.60-7.87 TH 7.87-8.19 F 8.07-8.21
And from last week:
M 7.19 -7.36 T 7.20-7.36 W 7.21-7.43 TH 7.25-7.54 F 7.47-7.55
Those of us who have been here a while can appreciate this moment in time. The company is performing well, with promise of the best yet to come in the pipeline, which is being reflected in the stock price.
Take a quick look at the highs and lows for the last two weeks. Every measure was higher (or in just one case the same) for the last 10 days of trading. That is extraordinarily cool. And the chart is really shaping up.
8 weeks ago, things did not look so bright for SPPI. Now, there’s a lot of blue on the horizon. Any pull backs at this time should be seen as a buying opportunity.
We close with a bit of groovy-ness from Thunderclap Newman. Just because it’s cool.
Dave Matthews Band's official music video for 'You And Me'. Click to listen to Dave Matthews Band on Spotify: http://smarturl.it/DMBSpot?IQid=DMBYM As featur...
POZIOTINIB RESULTS PRESENTATION (ABSTRACT AVAILABLE ON AUGUST 31ST)
Breast cancer, metastatic Chair(s) F. André (Villejuif, France) Session Type Proffered Paper session Details ESMO 2017 Congress, 2017-09-09, 11:00 - 12:30, Madrid Auditorium One LBA TBC 237O - A phase II trial of pan-HER inhibitor Poziotinib, in patients with HER2-positive metastatic breast cancer who have received at least two prior HER2-directed regimens: The results of NOV120101-203 trial. Y. Park (Seoul, Korea, Republic of)K. Lee (Seoul, Korea, Republic of)J. Sohn (Seoul, Korea, Republic of) K. Lee (Goyang, Korea, Republic of)K. Jung (Seoul, Korea, Republic of)J. Kim (Seongnam, Korea, Republic of) K. Lee (Cheongju, Korea, Republic of)J. Ahn (Seoul, Korea, Republic of)T. Kim (Seoul, Korea, Republic of) G. Kim (Seoul, Korea, Republic of)I. Park (Goyang, Korea, Republic of)S. Kim (Seoul, Korea, Republic of) S. Kim (Seongnam, Korea, Republic of)H. Han (Cheongju, Korea, Republic of)Y. Im (Seoul, Korea, Republic of) J. Ahn (Seoul, Korea, Republic of)J. Kim (Goyang, Korea, Republic of)J. Kang (Seoul, Korea, Republic of) S. Im (Seoul, Korea, Republic of) Invited Discussant one LBA TBC and 237O One LBA TBC One LBA TBC Invited Discussant two LBAs TBC
A new Qapzola phase 3 trial is posted, NCT03224182. Official Title: A Randomized, Single-Dose, Double-Blind, Placebo-CONtrolled Phase 3 Study of Qapzola™ (Apaziquone) as a Chemotherapy Adjuvant to TransUrEthral Resection of Bladder Tumors in Patients With Low- To-Intermediate-Risk NMIBC (CONQUER) It is a 500 patient trial with estimated Primary Completion date as January 2020. In the Description you can find: "Eligible patients will be randomized in a 2:1 ratio to either: •Arm 1: One dose of 8 mg Qapzola •Arm 2: One dose of placebo Once approved for randomization, patients will undergo TURBT on Day 1 and the study drug instillation will occur at 60 ± 30 minutes post-TURBT and will be retained for 60 minutes (±5 minutes) in the bladder."
Congrats to the longer timers! Finally broke and closed above $8. Over 2 1/2 years in the making. When this things really starts moving it will be fast and furious. We have known the catalysts for quite some time but predicting when the big boys will finally start jumping in with both feet has been another story.
Are algos attaching to the green heat?
I'm sure a lot of what is going on with the run-up of SPPI has to do with Options expiring tomorrow. We'll know for sure next week if the volume continues to be high and the price continues to rise!!
tick tock... 1st pozi patient treated 11/16/16 (now 8 months stable) pozi/MD Anderson trial enrolling - 50% or better enrolled? pozi - 100x more effective... standard of care? tick tock
I told wrong info, I believe the next quarterly report cones out in August, not next week.
Clinical trials updates: Both second phase 3 study and pharmacokinetics phase 1 study with Rolontis are now recruiting patients. Primary completion date for both trials is December 2017.
Spectrum Pharmaceuticals: Will Rolontis Substantially Increase Prospects?
Fusilev delivered opportunistic growth for Spectrum but earnings are now dependent on the six approved cancer drugs. Despite lackluster sales, approved therapeu
Preparing for massive sell off again. They are going to post another loss eps, multiple times this sky rockets and collapses near quarterly finances.
$9 price target BEFORE quarterly loss report is released
Analyst: STS Disclosure: long sppi
This has formed a nice cup and handle
Volume in first 30 minutes of trading kind of impressive today.....Heat maps heating up?
FDA approved Neratinib in breast cancer. From now on Spectrum really needs to focus on Poziotinib lung cancer program.
FDA approves Neratinib? If true, congrats to PBYI... SPPI is on the verge of greatness....Huge space, SPPI thinks they may be best in class...
A CT Order was filed yesterday for SPPI!
I see the stock in the 7.60's after the earnings CC.
Can anybody from the Talon acquisition days shed some light onto the status if the CVRs related to Marqibo and Menadione? They still appear to be worthless for now although a recent 10-K had some value assigned to them, is that correct? Thanks